慢性阻塞性肺疾病急性加重期合并肺动脉高压研究进展

朱师 雅*
青海大学临床医学院

摘要


慢性阻塞性肺疾病急性加重期（acute exacerbation of chronic obstructive pulmonary disease AECOPD）是一组慢性阻塞性肺疾病（COPD）患者在短期内出现咳嗽、气短，或喘息加重，咳量多脓性或黏液脓性痰，可伴发热等症状明显加重的表现。慢性阻塞性肺疾病急性加重的患者常并发多种并发症，其中肺动脉高压（Pulmonary arterial hypertension PAH）尤为常见。肺动脉高压不仅会加剧呼吸系统症状，还与增加心脏负荷、右心衰竭等严重心血管事件密切相关。近年来研究发现，AECOPD患者中的PAH发生率较高，诊断为PAH的患者常伴随更差的肺功能，出现更严重的气流受限情况。本文将从AECOPD合并PAH的流行病学、临床特征与诊治方面的进展作一综述，旨在为临床医生提供相关的理论支持。

关键词


慢性阻塞性肺疾病急性加重期；肺动脉高压；生物标志物；治疗管理

全文:

PDF


参考


[1]Ye H, Gu Y. Risk factors and establishment of a nomogram model for pulmonary arterial hypertension complicated by acute exacerbation of chronic obstructive pulmonary disease. Am J Transl Res. 2025 May 15;17(5):3917-3927.

[2]Mathioudakis AG, Janssens W, Sivapalan P,et al. Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits. Thorax. 2020 Jun;75(6):520-527.

[3]Olsson KM, Corte TJ, Kamp JC, et al. Pulmonary hypertension associated with lung disease: new insights into pathomechanisms, diagnosis, and management. Lancet Respir Med. 2023 Sep;11(9):820-835.

[4]Ruan H, Zhang H, Wang J, et al. Readmission rate for acute exacerbation of chronic obstructive pulmonary disease: A systematic review and meta-analysis. Respir Med. 2023 Jan;206:107090.

[5]Adeloye D, Chua S, Lee C, et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health. 2015;5(2):020415.

[6]Nathan SD, Barbera JA, Gaine SP, et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J. 2019 Jan 24;53(1):1801914.

[7]Balistrieri A, Makino A, Yuan JX. Pathophysiology and pathogenic mechanisms of pulmonary hypertension: role of membrane receptors, ion channels, and Ca2+ signaling. Physiol Rev. 2023 Jul 1;103(3):1827-1897.

[8]Grimmer B, Kuebler WM. The endothelium in hypoxic pulmonary vasoconstriction. J Appl Physiol (1985). 2017 Dec 1;123(6):1635-1646.

[9]Hu Y, Chi L, Kuebler WM, et al. Perivascular Inflammation in Pulmonary Arterial Hypertension. Cells. 2020 Oct 22;9(11):2338.

[10]Racanelli AC, Kikkers SA, Choi AMK, et al. Autophagy and inflammation in chronic respiratory disease. Autophagy. 2018;14(2):221-232.

[11]Gong Y, Du F, Yao Y, et al. Clinical Characteristics of Overweight Patients With Acute Exacerbation Chronic Obstructive Pulmonary Disease (AECOPD). Clin Respir J. 2024 Aug;18(8):e70001.

[12]You L, Niu H, Huang K, et al. Clinical Features and Outcomes of Acute Exacerbation in Chronic Obstructive Pulmonary Disease Patients with Pulmonary Heart Disease: A Multicenter Observational Study. Int J Chron Obstruct Pulmon Dis. 2021 Oct 22;16:2901-2910.

[13]Wells JM, Morrison JB, Bhatt SP, al. Pulmonary Artery Enlargement Is Associated With Cardiac Injury During Severe Exacerbations of COPD. Chest. 2016 May;149(5):1197-204.

[14]Feng L, Li J, Su J, et al. Increased in-hospital mortality and readmission risk associated with cardiovascular and cerebrovascular comorbidities in acute exacerbation of COPD patients. BMJ Open Respir Res. 2025 Sep 15;12(1):e003110.

[15]Wu XG, Shi YJ, Wang XH, Yu XW, Yang MX. Diagnostic value of computed tomography-based pulmonary artery to aorta ratio measurement in chronic obstructive pulmonary disease with pulmonary hypertension: A systematic review and meta-analysis. Clin Respir J. 2022 Apr;16(4):276-283.

[16]Weatherald J, Hemnes AR, Maron BA, et al. Gerges C, Price LC, Hoeper MM, Humbert M. Phenotypes in pulmonary hypertension. Eur Respir J. 2024 Sep 5;64(3):2301633.

[17]Mukherjee M, Rudski LG, Addetia K, et al. Guidelines for the Echocardiographic Assessment of the Right Heart in Adults and Special Considerations in Pulmonary Hypertension: Recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr. 2025 Mar;38(3):141-186. Erratum in: J Am Soc Echocardiogr. 2025 Jul;38(7):641.

[18]Guo FX, Zhu XC, Hu X, Chu DJ. The treatment of acute exacerbation of chronic obstructive pulmonary disease complicated by pulmonary arterial hypertension. Asian J Surg. 2022 Jan;45(1):590-591.

[19]Anderson S, Atkins P, Bäckman P, et al. Inhaled Medicines: Past, Present, and Future. Pharmacol Rev. 2022 Jan;74(1):48-118.

[20]Li Y, Wang Y, Liu S. Bosentan combined with sildenafil in the treatment of COPD patients with pulmonary arterial hypertension. Am J Transl Res. 2021 Oct 15;13(10):11522-11530.

[21]Padda IS, Tripp J. Phosphodiesterase Inhibitors. 2023 Jun 26. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.

[22]Zhang Y, Xu CB. The roles of endothelin and its receptors in cigarette smoke-associated pulmonary hypertension with chronic lung disease. Pathol Res Pract. 2020 Sep;216(9):153083.

[23]Zhang L, Zhang C, Dong F, et al. Combined pulmonary fibrosis and emphysema: a retrospective analysis of clinical characteristics, treatment and prognosis. BMC Pulm Med. 2016 Nov 3;16(1):137.

[24]Muñoz Montiel A, Ruiz-Esteban P, Doménech Del Río A, al. The effect of pulmonary rehabilitation on cardiovascular risk, oxidative stress and systemic inflammation in patients with COPD. Respir Med. 2024 Oct;232:107740.


Refbacks

  • 当前没有refback。